Abstract
Perforating dermatoses are characterized by transepithelial elimination of dermal structures. We report a 61-year-old man with rheumatoid arthritis who developed a perforating folliculitis following the administration of two tumour necrosis factor (TNF)-alpha inhibitors, infliximab and etanercept. To our knowledge, no perforating disorders have been reported associated with these drugs. This report suggests, for the first time, a role for TNF-alpha in the pathogenesis of perforating folliculitis.
MeSH terms
-
Antibodies, Monoclonal / adverse effects*
-
Antirheumatic Agents / adverse effects*
-
Arthritis, Rheumatoid / drug therapy*
-
Etanercept
-
Folliculitis / chemically induced*
-
Folliculitis / pathology
-
Humans
-
Immunoglobulin G / adverse effects*
-
Infliximab
-
Male
-
Middle Aged
-
Receptors, Tumor Necrosis Factor
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Substances
-
Antibodies, Monoclonal
-
Antirheumatic Agents
-
Immunoglobulin G
-
Receptors, Tumor Necrosis Factor
-
Tumor Necrosis Factor-alpha
-
Infliximab
-
Etanercept